A5101497029- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- Mass Spectrometry Techniques and Applications
- CAR-T cell therapy research
- Hemoglobinopathies and Related Disorders
- Virus-based gene therapy research
- Pharmacological Effects and Toxicity Studies
- Cutaneous Melanoma Detection and Management
- HIV/AIDS Research and Interventions
- Healthcare Systems and Technology
- Atrial Fibrillation Management and Outcomes
- Neurofibromatosis and Schwannoma Cases
- Genomics and Rare Diseases
- Epilepsy research and treatment
- Healthcare Operations and Scheduling Optimization
- BRCA gene mutations in cancer
- Colorectal and Anal Carcinomas
- Gastrointestinal Tumor Research and Treatment
- Ethics in Clinical Research
- Polyomavirus and related diseases
- Radiomics and Machine Learning in Medical Imaging
- Adolescent Sexual and Reproductive Health
- Hematopoietic Stem Cell Transplantation
Cornell University
2020-2025
Weill Cornell Medicine
2020-2025
Bristol-Myers Squibb (United States)
2025
University of Tennessee Health Science Center
2024
Presbyterian Hospital
2024
Loma Linda University
2019-2024
Loma Linda University Medical Center
2019-2024
New York Hospital Queens
2024
NewYork–Presbyterian Hospital
2024
New York Institute of Technology
2022
<h3>Importance</h3> Strides to improve survival in metastatic melanoma have been made with the use of immunotherapeutic agents form immune checkpoint inhibitors. <h3>Objective</h3> To examine factors associated immunotherapy receipt patients era inhibitors and Patient Protection Affordable Care Act. <h3>Design, Setting, Participants</h3> This cohort study used data on 9882 diagnosed from January 1, 2013, December 31, 2016, National Cancer Database. Patients who did not documentation...
185 Background: Targeted radionucleotide therapy (TRT) has become a standard of care. α-emitters have higher energy transfer over shorter range than β-emitters. PSMA-targeting antibodies different biodistribution small molecules and may improve intracellular retention based on pre-clinical models. Here, we present mature follow up phase 1 dose-escalation trial 225Ac-J591 plus 177Lu-PSMA-I&T (aka PNT2002). Methods: Inclusion criteria:progressive mCRPC with ≥1 prior AR pathway inhibitor...
Patients with refractory or recurrent B-lineage hematologic malignancies have less than 50% of chance cure despite intensive therapy and innovative approaches are needed. We hypothesize that gene modification haematopoietic stem cells (HSC) an anti-CD19 chimeric antigen receptor (CAR) will produce a multi-lineage, persistent immunotherapy against can be controlled by the HSVsr39TK suicide gene. High-titer third-generation self-inactivating lentiviral constructs were developed to deliver...
TPS288 Background: As prostate-specific membrane antigen targeted radiotherapy (PSMA-TRT) is now an active standard-of-care treatment in mCRPC, ongoing studies with alternative approaches to targeting PSMA will increasingly need consider the consequences of sequential PSMA-TRT exposure. Our past and investigations into antibody-based (e.g., J591) potent alpha emitting payloads 225Ac) impact drug kinetics, biodistribution, resultant clinical toxicities. In a first-in-human phase I...
5018 Background: PSMA may be targeted by antibodies (mAb) or small molecules (SML), with different kinetics and biodistribution. mAb longer circulation time marrow exposure, but decreased access to luminal expression (e.g. salivary glands, intestine, kidney). SML diffuse all sites of then excreted. Alpha radionuclides emit more energy over shorter range vs beta. Pre-clinical data combining supports synergy, enhanced uptake retention SML. Here, we present phase I dose-escalation results a...
Abstract Introduction: Predictors of outcomes after PSMA-TRT are still being established. Liver metastases (mets) have been associated with poor response. Mutations in genes encoding DNA damage repair (DDR) and TP53 affect radiosensitivity. Here we describe a cohort patients mCRPC liver treated on clinical trials PSMA-TRT. Methods: 39 mets were enrolled phase I/II studies between Jan 2006 to Apr 2022. Patients received alpha therapy (225Ac-J591), beta (fractionated 177Lu-PSMA-617,...
5074 Background: PC commonly expresses PSMA and has dose-responsive radiosensitivity. 177 Lu-based radioligands usually use an empiric dosing regimen. This 1st dose-escalation study of Lu-PSMA-617 employed a dose-dense fractionation schedule intended to allow delivery higher total doses overcome radioresistance due repopulation. Here, we report mature results the study. Methods: Progressive mCRPC following > 1 potent ARPI (e.g., abi/enza) chemo (or unfit/refuse taxane) without limit #...
TPS216 Background: The role of immune checkpoint inhibition (ICI) in prostate cancer remains undefined outside the subset with mismatch repair. Several studies have suggested that ICI combined androgen receptor signaling inhibitors (ARSI) or kinase may result improved and/or more durable response a proportion men mCRPC. While not yet proven, addition external beam radiation to improve outcomes (for instance Kwon et al Lancet Oncol 2014, Fizazi K al, Eur Urol 2020). PSMA targeted therapy...
Background Hidradenitis suppurativa (HS) is a clinical condition characterized by the formation of painful lumps under skin. It often affects intertriginous areas like armpits and groin. There paucity contemporary data on patient hospital-level characteristics HS in United States. Methods We analyzed Nationwide Inpatient Sample (NIS) for retrospective analysis to calculate frequency yearly rates hospitalizations, demographic variations, comorbidities, length stay. Results The rate...
Abstract Background: PSMA-based targeted radionuclide therapy is now a standard of care for mCRPC since approval 177Lu-PSMA-617. Use antibodies (e.g., J591) to target PSMA with higher potency radionuclides 225Ac) impacts kinetics, biodistribution, clinical efficacy, and toxicities. In our first-in-human ph I dose-escalation study single dose 225Ac-J591 in patients mCRPC, no MTD was reached (max 93.3 KBq/kg). Following this, we developed I/II parallel studies fractionated (D1, D15) cycle...
Abstract Introduction: Even after curative intent resection, stage III melanoma carries poor prognosis and traditional chemotherapy has limited efficacy. Adjuvant immune checkpoint inhibitor (ICI) therapy utilizing the anti-CTLA-4 agent, ipilimumab, was shown to improve survival following resection in Stage disease. Ipilimumab FDA approved for adjuvant 2015. The National Cancer Database (NCDB) is a joint project of Commission on American College Surgeons Society largest clinical cancer...
This quality improvement initiative aimed to reduce the no-show rate at a hospital-based tertiary sickle cell ophthalmology clinic. Missed appointments place significant burden on healthcare system, resulting in prolonged waiting times and underutilized clinical resources that impact of care provided. Individuals with disease commonly require multiple address myriads comorbidities associated their disease. Nevertheless, clinic experienced an alarmingly high 49% from June September 2021...
A 8 year-old female with sickle cell disease diagnosed at birth was confirmed to have neurofibromatosis type 1 13 months of age. At 7 years old, she noted incidental papilledema subsequent workup showing elevated opening pressure. She intracranial hypertension and began treatment acetazolamide the discontinuation hydroxyurea. Acetazolamide tapered off hydroxyurea restarted no worsening in her ophthalmologic exam. We report this case due rare occurrence all three conditions as well delineate...
Abstract Background: We have previously reported that 177Lu-PSMA-617 given as a single-cycle, dose-intense regimen for patients (pts) with pretreated mCRPC is efficacious even without selection by PSMA (ESMO 2021). Quantitative analyses of pre-treatment PET may allow better patient and prediction toxicities. Analyses sequential images also provide insights be associated longer term outcomes. Our previous analysis 13 demonstrated association signal overall survival (OS) PSA responses, well...
You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) I (PD01)1 May 2024PD01-11 PHASE DOSE-ESCALATION TRIAL OF MULTIPLE AND FRACTIONATED-DOSE PSMA-TARGETED ALPHA RADIONUCLIDE (225AC-J591) FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Michael Sun, Jones Nauseef, Andrés Ricaurte Fajardo, Zachary Davidson, Joseph Thomas, Samuel Ruder, Judith Stangl-Kremser, Sandra Huicochea Castellanos, Ana Molina, Cora Sternberg, Amie Patel, Sarah Yuan, Escarleth Fernandez,...
87 Background: Metastatic melanoma carries poor prognosis and traditional chemotherapy has limited efficacy, but immune checkpoint inhibitors (ICIs) have drastically improved disease outcomes since first approved in 2011. Access to these costly agents the real-world setting can be challenging. We aimed assess demographic socioeconomic factors associated with receipt of immunotherapy Stage IV using National Cancer Database (NCDB). Methods: NCDB classified ICIs as 2013, hence we queried...
A pediatric female with sickle cell disease (SCD) and neurofibromatosis type 1 was noted to have incidental papilledema, subsequent workup showing an elevated opening pressure. She diagnosed intracranial hypertension began treatment acetazolamide. Hydroxyurea also discontinued. Acetazolamide tapered off, hydroxyurea restarted no worsening in her ophthalmologic exam. We report this case due the rare occurrence of all 3 conditions, while has been reported SCD, diagnostic for papilledema...